PowerPort Catheter Migration — Where Fragments Go

The Anatomical Path of a Migrating Fragment

When a PowerPort catheter fractures, the detached segment becomes an intravascular foreign body embolus in the central venous system. Because the catheter tip sits in the superior vena cava (SVC) just above the right atrium, the fragment is immediately in a high-flow venous location. Venous blood flow carries the fragment in a predictable anatomical sequence: superior vena cava → right atrium → right ventricle → pulmonary valve → main pulmonary artery → right or left pulmonary artery → lobar and segmental pulmonary artery branches. The fragment may come to rest at any point along this path depending on its size, shape, and the pulmonary vascular anatomy of the individual patient.

Smaller, more flexible fragments are more likely to pass through the right heart into the pulmonary circulation and lodge in peripheral pulmonary artery branches, where they are more difficult to retrieve percutaneously. Larger or stiffer fragments are more likely to become entrapped in the right ventricle or main pulmonary artery, where they are associated with higher rates of cardiac arrhythmia and perforation risk but are also more accessible for percutaneous retrieval. In some cases, fragments coil around the chordae tendineae (heart valve support structures) in the right ventricle, making retrieval particularly challenging.

Cardiac Risks from Fragment Lodgment in the Heart

A catheter fragment lodged in the right ventricle poses acute cardiac risks. The right ventricular apex is thin-walled (2-3 mm) and the fragment's sharp end can penetrate the myocardium, causing hemopericardium (blood in the pericardial sac) and cardiac tamponade — progressive compression of the heart that reduces cardiac output and causes hemodynamic collapse if untreated. Even without perforation, a right ventricular fragment acts as an arrhythmic focus, causing ventricular ectopic beats, ventricular tachycardia, and in severe cases, ventricular fibrillation. The mechanical irritation of the endocardial surface also promotes thrombus formation on the fragment, creating additional embolic risk.

Fragments that cross the tricuspid or pulmonary valve can damage valve leaflets, causing valvular regurgitation — backward leakage of blood — that reduces cardiac efficiency and over time leads to right-sided heart failure. Bacterial colonization of valve-adjacent fragments causes infective endocarditis with vegetation formation, which can embolize to the lungs and systemic circulation, causing septic pulmonary emboli, stroke, and multi-organ infection.

Pulmonary Risks from Fragment in the Lungs

Fragments that migrate into the pulmonary arterial tree cause several categories of injury. Direct obstruction of a pulmonary arterial branch reduces blood flow to the affected lung segment, causing ischemia and potentially pulmonary infarction — death of lung tissue. The inflammatory response to the foreign body promotes local clot formation, which can propagate to cause more extensive pulmonary embolism. Chronic obstruction of pulmonary arterial branches by fragments and associated thrombus can cause chronic thromboembolic pulmonary hypertension (CTEPH) — elevated pressure in the pulmonary vasculature that progressively impairs right ventricular function and oxygen exchange capacity.

CTEPH is an insidious complication because it develops gradually — patients experience progressive exertional dyspnea, reduced exercise tolerance, and fatigue over months before the condition is diagnosed. By the time CTEPH is recognized, significant pulmonary vascular remodeling may have occurred that limits the benefit of therapeutic intervention. Treatment requires specialized pulmonary vasodilator medications and in selected cases, pulmonary thromboendarterectomy (PTE) surgery at a specialized center. CTEPH-related disability from a PowerPort catheter fragment is a significant component of damages in affected plaintiffs' cases.